BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 10585797)

  • 1. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis.
    Souza JP; Boeckh M; Gooley TA; Flowers ME; Crawford SW
    Clin Infect Dis; 1999 Dec; 29(6):1467-71. PubMed ID: 10585797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of once-weekly dapsone dosing for Pneumocystis jirovecii pneumonia prophylaxis post transplantation.
    Evans RA; Clifford TM; Tang S; Au T; Fugit AM
    Transpl Infect Dis; 2015 Dec; 17(6):816-21. PubMed ID: 26369753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapsone for Pneumocystis carinii prophylaxis in children undergoing bone marrow transplantation.
    Maltezou HC; Petropoulos D; Choroszy M; Gardner M; Mantzouranis EC; Rolston KV; Chan KW
    Bone Marrow Transplant; 1997 Nov; 20(10):879-81. PubMed ID: 9404930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clindamycin/primaquine as prophylaxis for Pneumocystis carinii pneumonia.
    Barber BA; Pegram PS; High KP
    Clin Infect Dis; 1996 Oct; 23(4):718-22. PubMed ID: 8909833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia.
    Warnock AC; Rimland D
    Pharmacotherapy; 1996; 16(6):1030-8. PubMed ID: 8947975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients.
    Urbancic KF; Pisasale D; Wight J; Trubiano JA
    Transpl Infect Dis; 2018 Dec; 20(6):e12968. PubMed ID: 30030892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections.
    Vasconcelles MJ; Bernardo MV; King C; Weller EA; Antin JH
    Biol Blood Marrow Transplant; 2000; 6(1):35-43. PubMed ID: 10707997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atovaquone versus trimethoprim-sulfamethoxazole as Pneumocystis jirovecii pneumonia prophylaxis following renal transplantation.
    Gabardi S; Millen P; Hurwitz S; Martin S; Roberts K; Chandraker A
    Clin Transplant; 2012; 26(3):E184-90. PubMed ID: 22487221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lower risk of urinary tract infection with low-dose trimethoprim/sulfamethoxazole compared to dapsone prophylaxis in older renal transplant patients on a rapid steroid-withdrawal immunosuppression regimen.
    Giullian JA; Cavanaugh K; Schaefer H
    Clin Transplant; 2010; 24(5):636-42. PubMed ID: 19925478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study.
    Sangiolo D; Storer B; Nash R; Corey L; Davis C; Flowers M; Hackman RC; Boeckh M
    Biol Blood Marrow Transplant; 2005 Jul; 11(7):521-9. PubMed ID: 15983552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of dosages, intervals, and drugs in the prevention of Pneumocystis carinii pneumonia.
    Hughes WT
    Antimicrob Agents Chemother; 1988 May; 32(5):623-5. PubMed ID: 3260765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of dapsone as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole.
    Beumont MG; Graziani A; Ubel PA; MacGregor RR
    Am J Med; 1996 Jun; 100(6):611-6. PubMed ID: 8678080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus.
    Simonds RJ; Hughes WT; Feinberg J; Navin TR
    Clin Infect Dis; 1995 Aug; 21 Suppl 1():S44-8. PubMed ID: 8547511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Guidelines for Prevention of Pneumocystis carinii Pneumonitis in Children and Adolescents with Cancer].
    Groll AH; Ritter J; Müller FM
    Klin Padiatr; 2001 Sep; 213 Suppl 1():A38-49. PubMed ID: 11577363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation.
    Colby C; McAfee S; Sackstein R; Finkelstein D; Fishman J; Spitzer T
    Bone Marrow Transplant; 1999 Oct; 24(8):897-902. PubMed ID: 10516703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability of low-dose sulfamethoxazole/trimethoprim for Pneumocystis jirovecii pneumonia prophylaxis in kidney transplant recipients.
    Zmarlicka M; Martin ST; Cardwell SM; Nailor MD
    Prog Transplant; 2015 Sep; 25(3):210-6. PubMed ID: 26308779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Pneumocystis carinii pneumonia in patients with AIDS.
    Wordell CJ; Hauptman SP
    Clin Pharm; 1988 Jul; 7(7):514-27. PubMed ID: 3138063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review.
    Hughes WT
    Clin Infect Dis; 1998 Jul; 27(1):191-204. PubMed ID: 9675476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study.
    Saah AJ; Hoover DR; Peng Y; Phair JP; Visscher B; Kingsley LA; Schrager LK
    JAMA; 1995 Apr; 273(15):1197-202. PubMed ID: 7707627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful desensitization to dapsone for Pneumocystis carinii prophylaxis in an HIV-positive patient.
    Cook DE; Kossey JL
    Ann Pharmacother; 1998 Dec; 32(12):1302-5. PubMed ID: 9876811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.